Suven Life Sciences responds to BSE surveillance letter regarding recent stock volume movement.
Company confirms no material events requiring disclosure under SEBI LODR Regulation 30.
Attributes recent price/volume behavior to market speculation with no further comment.
Requests dissemination of this clarification on BSE website and company portal.